MCID: NRP001
MIFTS: 58

Neuropathy

Categories: Immune diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Neuropathy

Summaries for Neuropathy

Disease Ontology: 11 A nervous system disease that is located in nerves or nerve cells.

MalaCards based summary: Neuropathy, also known as peripheral neuropathy, is related to neuropathy, hereditary, with liability to pressure palsies and neuropathy, hereditary sensory and autonomic, type iia, and has symptoms including tremor, back pain and headache. An important gene associated with Neuropathy is DLX6-AS1 (DLX6 Antisense RNA 1), and among its related pathways/superpathways are Neural crest differentiation and EGR2 and SOX10-mediated initiation of Schwann cell myelination. The drugs Bevacizumab and Carbidopa have been mentioned in the context of this disorder. Affiliated tissues include nerves, dorsal root ganglion and bone marrow, and related phenotypes are nervous system and growth/size/body region

Related Diseases for Neuropathy

Diseases in the Neuropathy family:

Autoimmune Neuropathy Hereditary Neuropathies

Diseases related to Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3240)
# Related Disease Score Top Affiliating Genes
1 neuropathy, hereditary, with liability to pressure palsies 33.4 PRX PMP22 MTMR2 MPZ MFN2 GJB1
2 neuropathy, hereditary sensory and autonomic, type iia 33.3 WNK1 SPTLC1 SLC12A6 POLG NGF MFN2
3 peripheral nervous system disease 33.3 SPTLC1 SLC12A6 PRX POLG PNPLA6 PMP22
4 leber hereditary optic neuropathy, modifier of 33.2 POLG MT-ND6 MT-ND4 MFN2
5 neuromyotonia and axonal neuropathy, autosomal recessive 33.2 MPZ MFN2 GJB1
6 neuropathy, congenital hypomyelinating, 1, autosomal recessive 33.2 SLC12A6 PRX PMP22 MTMR2 MPZ MFN2
7 diabetic neuropathy 33.2 PMP22 NGF MPZ
8 neuropathy, ataxia, and retinitis pigmentosa 33.1 POLG MT-ND6 MT-ND4
9 hereditary sensory neuropathy 33.1 WNK1 SPTLC1 NGF MPZ GDAP1
10 neuropathy, hereditary sensory and autonomic, type v 33.1 WNK1 SPTLC1 NGF
11 sensory peripheral neuropathy 33.1 SPTLC1 SLC12A6 PRX POLG PMP22 NGF
12 hypertrophic neuropathy of dejerine-sottas 33.1 PRX PMP22 MTMR2 MPZ MFN2 GJB1
13 optic nerve disease 33.0 POLG NGF MT-ND6 MT-ND4 MFN2 GDAP1
14 autonomic neuropathy 33.0 WNK1 SPTLC1 NGF
15 charcot-marie-tooth disease, axonal, type 2e 33.0 SPTLC1 PRX PMP22 NGF MTMR2 MPZ
16 neuronopathy, distal hereditary motor, type va 33.0 MPZ MFN2 GDAP1
17 neuropathy, hereditary sensory and autonomic, type ic 33.0 SPTLC1 MPZ GJB1
18 charcot-marie-tooth disease, x-linked dominant, 1 33.0 SPTLC1 PMP22 MTMR2 MPZ MFN2 GJB1
19 charcot-marie-tooth disease and deafness 33.0 SPTLC1 PRX PMP22 MTMR2 MPZ MFN2
20 hereditary neuropathies 32.9 PRX PMP22 MTMR2 MPZ MFN2 GJB1
21 neuropathy, hereditary sensory and autonomic, type ia 32.9 WNK1 SPTLC1
22 charcot-marie-tooth disease, demyelinating, type 1b 32.9 PRX PMP22 MTMR2 MPZ MFN2 GJB1
23 charcot-marie-tooth disease, demyelinating, type 1a 32.8 SPTLC1 PRX PMP22 MTMR2 MPZ MFN2
24 charcot-marie-tooth disease, axonal, type 2b 32.8 SPTLC1 MTMR2 MPZ MFN2 GJB1 GDAP1
25 hereditary motor and sensory neuropathy, type iic 32.8 MTMR2 MPZ MFN2 GJB1 GDAP1
26 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 32.8 PMP22 MPZ GJB1 EGR2
27 ulnar neuropathy 32.8 PMP22 MPZ
28 neuropathy, hereditary motor and sensory, russe type 32.8 MTMR2 GDAP1
29 charcot-marie-tooth disease, type 4d 32.8 MTMR2 MPZ GJB1 GDAP1 EGR2
30 charcot-marie-tooth disease, demyelinating, type 1c 32.8 PRX PMP22 MTMR2 MPZ GJB1 GDAP1
31 deafness, x-linked 5, with peripheral neuropathy 32.8 DIAPH3 AIFM1
32 charcot-marie-tooth disease, axonal, type 2a1 32.8 MPZ MFN2 GDAP1
33 auditory neuropathy, autosomal dominant 1 32.8 DIAPH3 AIFM1
34 charcot-marie-tooth disease, dominant intermediate b 32.7 MTMR2 MPZ GJB1 GDAP1
35 charcot-marie-tooth disease, demyelinating, type 1f 32.7 PMP22 MTMR2 MPZ GJB1
36 nerve compression syndrome 32.7 PMP22 NGF MPZ
37 motor peripheral neuropathy 32.7 SLC12A6 PMP22 MFN2
38 charcot-marie-tooth disease 32.7 SPTLC1 SLC12A6 PRX POLG PMP22 NGF
39 agenesis of the corpus callosum with peripheral neuropathy 32.7 WNK1 SLC12A6
40 hereditary optic neuropathy 32.7 MT-ND6 MT-ND4
41 charcot-marie-tooth disease, axonal, type 2p 32.7 MPZ GDAP1 GAN
42 axonal neuropathy 32.7 POLG MFN2 GDAP1 GAN AIFM1
43 charcot-marie-tooth disease, type 4a 32.7 PRX MTMR2 MPZ MFN2 GJB1 GDAP1
44 charcot-marie-tooth disease, axonal, type 2d 32.7 MPZ MFN2 GJB1 GDAP1
45 charcot-marie-tooth disease, type 4b2 32.7 PRX MTMR2 MPZ MFN2 GJB1 GDAP1
46 charcot-marie-tooth disease, recessive intermediate a 32.7 MFN2 GJB1 GDAP1
47 charcot-marie-tooth disease type 2a2b 32.7 MTMR2 MPZ MFN2 GDAP1
48 polyneuropathy 32.7 PRX POLG PNPLA6 PMP22 NGF MPZ
49 charcot-marie-tooth disease, type 4b1 32.6 PRX MTMR2 MPZ GDAP1
50 charcot-marie-tooth disease, axonal, type 2f 32.6 MTMR2 MPZ MFN2 GJB1 GDAP1

Graphical network of the top 20 diseases related to Neuropathy:



Diseases related to Neuropathy

Symptoms & Phenotypes for Neuropathy

UMLS symptoms related to Neuropathy:


tremor; back pain; headache; syncope; hemiparesis; pain; chronic pain; sciatica; seizures; vertigo/dizziness; sleeplessness; neuralgia; neurologic symptoms; atypical facial pain

GenomeRNAi Phenotypes related to Neuropathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 AIFM1 DIAPH3 EGR2 GAN GDAP1 GJB1
2 no effect GR00402-S-2 10.13 AIFM1 DIAPH3 EGR2 GAN GDAP1 MFN2

MGI Mouse Phenotypes related to Neuropathy:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.46 AIFM1 DLX6-AS1 EGR2 GAN GDAP1 GJB1
2 growth/size/body region MP:0005378 10.36 AIFM1 DIAPH3 EGR2 GAN GJB1 MFN2
3 homeostasis/metabolism MP:0005376 10.32 AIFM1 DIAPH3 EGR2 GDAP1 GJB1 MFN2
4 cellular MP:0005384 10.22 AIFM1 DIAPH3 EGR2 GAN GDAP1 GJB1
5 behavior/neurological MP:0005386 10.2 AIFM1 DIAPH3 EGR2 GAN GDAP1 GJB1
6 muscle MP:0005369 10.15 AIFM1 GAN MFN2 MT-ND6 NGF PMP22
7 cardiovascular system MP:0005385 10.07 AIFM1 DIAPH3 EGR2 MFN2 MT-ND6 NGF
8 embryo MP:0005380 10.03 AIFM1 DIAPH3 EGR2 MFN2 PNPLA6 POLG
9 reproductive system MP:0005389 9.96 EGR2 GDAP1 MFN2 MPZ MTMR2 MT-ND6
10 vision/eye MP:0005391 9.81 AIFM1 DIAPH3 EGR2 GJB1 MT-ND6 NGF
11 mortality/aging MP:0010768 9.8 AIFM1 DIAPH3 EGR2 GAN GJB1 MFN2
12 integument MP:0010771 9.28 AIFM1 DIAPH3 EGR2 GDAP1 MPZ NGF

Drugs & Therapeutics for Neuropathy

Drugs for Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 492)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3 135329020
2
Carbidopa Approved Phase 4 28860-95-9 34359 38101
3
Levodopa Approved Phase 4 59-92-7, 63-84-3 6047
4
Dalfampridine Approved Phase 4 504-24-5 1727
5
Mexiletine Approved, Investigational Phase 4 5370-01-4, 31828-71-4 4178
6
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
7
Histamine Approved, Investigational Phase 4 51-45-6 774
8
Amitriptyline Approved Phase 4 50-48-6 2160
9
Nortriptyline Approved Phase 4 72-69-5 4543
10
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
11
Nabilone Approved, Investigational Phase 4 51022-71-0 39860 5284592
12
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
13
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
14
Dapagliflozin Approved Phase 4 461432-26-8 9887712
15
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
16
Cetirizine Approved Phase 4 83881-51-0 2678
17
Lacosamide Approved Phase 4 175481-36-4 21634109 219078
18
Mecobalamin Approved, Investigational Phase 4 13422-55-4
19
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
20
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
21
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
22
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
23
Topiramate Approved Phase 4 97240-79-4 5284627
24
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537 59227
25
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
26
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
27
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
28
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
29
Pramipexole Approved, Investigational Phase 4 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868
30
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857
31
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
32
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
33
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
34
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
35
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
36
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
37
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
38
Norepinephrine Approved Phase 4 51-41-2 439260
39
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
40
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
41
Tapentadol Approved Phase 4 175591-23-8 9838022
42
Donepezil Approved Phase 4 120014-06-4 3152
43
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1200-22-2 864 6112
46
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
47
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
48
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
49
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
50
Cobalamin Experimental Phase 4 13408-78-1 6857388

Interventional clinical trials:

(show top 50) (show all 1369)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
2 The Effects of Omega-3 Fatty Acids on Chemotherapy-induced Neuropathy and Inflammation in Patients With Breast Cancer Unknown status NCT01049295 Phase 4
3 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
5 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
6 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
7 The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
8 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
9 Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Citicoline
10 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
11 Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
12 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
13 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
14 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
15 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
16 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
17 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
18 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
19 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
20 External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) Completed NCT02774005 Phase 4 Idebenone
21 Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain Completed NCT02074267 Phase 4 Carbatin;Neurontin
22 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study Completed NCT02056366 Phase 4 α-lipoic acid
23 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
24 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
25 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
26 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
27 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
28 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
29 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
30 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
31 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm
32 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
33 Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of Tegretol® in Diabetes Neuropathy Pain. Completed NCT01089855 Phase 4 Carbamazepine
34 A Comparative Study Of Botulinum Toxin Type A Versus Conventional Oral Therapy As A Second Line Treatment Of Diabetic Neuropathy Completed NCT05296759 Phase 4 botulinum toxin A;Gabapentin;Duloxetine
35 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
36 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
37 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
38 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
39 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
40 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
41 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
42 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
43 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
44 A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
45 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
46 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
47 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
48 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
49 Efficacy of Pregabalin in Patients With Radicular Pain Completed NCT00908375 Phase 4 Pregabalin;Sugar Pill
50 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride

Search NIH Clinical Center for Neuropathy

Genetic Tests for Neuropathy

Anatomical Context for Neuropathy

Organs/tissues related to Neuropathy:

FMA: Nerves
MalaCards : Dorsal Root Ganglion, Bone Marrow, Spinal Cord, Breast, Skin, Brain, Placenta

Publications for Neuropathy

Articles related to Neuropathy:

(show top 50) (show all 44910)
# Title Authors PMID Year
1
Charcot-Marie-Tooth-1A and sciatic nerve crush rat models: insights from proteomics. 62
36453423 2023
2
Hydrogen exerts neuroprotective effects by inhibiting oxidative stress in experimental diabetic peripheral neuropathy rats. 62
36204786 2023
3
Nonarteritic Anterior Ischemic Optic Neuropathy: Cystic Change in the Inner Nuclear Layer Caused by Edema and Retrograde Maculopathy. 62
36439696 2023
4
Temporal Alterations of Sphingolipids in Optic Nerves After Indirect Traumatic Optic Neuropathy. 62
36275202 2023
5
The alteration of the expression level of neuropathy target esterase in human neuroblastoma SK-N-SH cells disrupts cellular phospholipids homeostasis. 62
36336212 2023
6
Establishment of a minimally invasive distal traumatic optic neuropathy model in mice to investigate cascade reactions of retinal glial cells. 62
36468758 2023
7
Towards a mechanistic understanding of axon transport and endocytic changes underlying paclitaxel-induced peripheral neuropathy. 62
36279934 2023
8
Aging Muscles, Myositis, Pain, and Peripheral Neuropathies: PET Manifestations in the Elderly. 62
36442962 2023
9
Investigating the synergistic role of heavy metals in Arsenic-induced skin lesions in West Bengal, India. 62
36435151 2023
10
Migraine Headaches in Patients with Upper Extremity Compressive Neuropathy. 62
36161789 2022
11
SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study. 62
35732222 2022
12
Low T3 syndrome is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. 62
36089765 2022
13
Skin advanced glycation end products as a screening tool of neuropathy in type 2 diabetes mellitus. 62
36395605 2022
14
Mosaic vs. Single Image Analysis with Confocal Microscopy of the Corneal Nerve Plexus for Diagnosis of Early Diabetic Peripheral Neuropathy. 62
36184730 2022
15
Small fiber neuropathy in hypermobile Ehlers Danlos syndrome/hypermobility spectrum disorder. 62
35781355 2022
16
Anxiety and depression in small fiber neuropathy. 62
36168866 2022
17
Acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature. 62
35962630 2022
18
The diagnostic accuracy of the small fiber neuropathy symptoms inventory questionnaire (SFN-SIQ) for identifying pure small fiber neuropathy. 62
36175394 2022
19
Immunoglobulin Use for the Management of Painful Peripheral Neuropathy: A Systematic Review and Meta-Analysis. 62
35925489 2022
20
Alcoholic neuropathy associated with chronic alcohol intake. 62
36065406 2022
21
Small-fibre neuropathy in patients with familial Amyotrophic Lateral Sclerosis type 8. 62
36457144 2022
22
The SPTLC1 p.S331 mutation bridges sensory neuropathy and motor neuron disease and has implications for treatment. 62
35904184 2022
23
Neuropathic upper extremity pain: A double-crush scenario. 62
36412937 2022
24
Vitamin D Status in a Bulgarian Population With Type 2 Diabetes and Diabetic Foot Ulcers. 62
33094656 2022
25
Blinding Anemia: A Case of Bilateral Sequential Nonarteritic Ischemic Optic Neuropathy Secondary to Warm Autoimmune Hemolytic Anemia. 62
34803137 2022
26
Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes. 62
35944243 2022
27
Alterations in Functional Connectivity of Thalamus and Primary Somatosensory Cortex in Painful and Painless Diabetic Peripheral Neuropathy. 62
36469731 2022
28
Clinical scoring systems for the risk of cardiovascular autonomic neuropathy in type 1 and type 2 diabetes: A simple tool. 62
36029134 2022
29
A case of herpes zoster ophthalmicus with optic neuritis of the total length of the optic nerve in the orbital space and ischemic optic neuropathy. 62
36467120 2022
30
Peripapillary Microvascular and Structural Parameters in Atrophic Nonarteritic Anterior Ischemic Optic Neuropathy and Their Unaffected Fellow Eyes. 62
35421878 2022
31
Construction and functional enrichment analysis of the competitive endogenous RNA regulatory network for nonarteritic anterior ischemic optic neuropathy based on high-throughput sequencing. 62
36355332 2022
32
Upregulation of retinal VEGF and connexin 43 in murine nonarteritic anterior ischemic optic neuropathy induced with 577 nm laser. 62
35691373 2022
33
Perioperative Ischemic Optic Neuropathy after Cardiac Surgery: Development and Validation of a Preoperative Risk Prediction Model. 62
36114093 2022
34
Bilateral Optic Nerve Enhancement in Posterior Ischemic Optic Neuropathy Secondary to Hypovolemic Shock. 62
36394970 2022
35
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. 62
36111430 2022
36
Dysthyroid optic neuropathy: Demographics, risk factors, investigations, and management outcomes. 62
36453357 2022
37
Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease. 62
36092250 2022
38
The epidemiology and mutation types of Leber's hereditary optic neuropathy in Thailand. 62
35723074 2022
39
Quantitative assessment of macular and circumpapillary retinal vessel density across all stages of Leber hereditary optic neuropathy using swept source optical coherence tomography angiography. 62
35524395 2022
40
A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. 62
36057884 2022
41
Clinical features of NOTCH2NLC-related neuronal intranuclear inclusion disease. 62
36150844 2022
42
Oral Nanocurcumin Alone or in Combination with Insulin Alleviates STZ-Induced Diabetic Neuropathy in Rats. 62
36106748 2022
43
Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion. 62
36398590 2022
44
Konzepte der Sturzrisikoabschätzung bei neurogeriatrischen Patienten. 62
36459999 2022
45
Cisplatin-induced changes in calcitonin gene-related peptide or TNF-α release in rat dorsal root ganglia in vitro model of neurotoxicity are not reverted by rosiglitazone. 62
36228751 2022
46
Emerging roles of toll-like receptor 4 in chemotherapy-induced neurotoxicity. 62
36152729 2022
47
Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. 62
35859244 2022
48
A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study. 62
36151017 2022
49
Glaucomatous optic neuropathy in relation to 24-h ambulatory blood pressure monitoring. 62
36445422 2022
50
Erratum to "Optic neuropathy in a COVID-19 patient" [J. Fr. Ophtalmol. 45 (2022) 1271-1273]. 62
36464528 2022

Variations for Neuropathy

Copy number variations for Neuropathy from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107544 17 15900000 22100000 Microdeletion Neuropathy
2 107574 17 16000000 22200000 Copy number Neuropathy
3 216423 6 92100000 98700000 Microdeletion EPHA7 Neuropathy

Expression for Neuropathy

Search GEO for disease gene expression data for Neuropathy.

Pathways for Neuropathy

Pathways related to Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.34 PMP22 MPZ GJB1
2 10.7 PRX PMP22 MPZ EGR2
3 10.53 PMP22 MTMR2 MPZ MFN2 GDAP1 EGR2

GO Terms for Neuropathy

Biological processes related to Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial respiratory chain complex I assembly GO:0032981 9.65 MT-ND6 MT-ND4 AIFM1
2 myelin assembly GO:0032288 9.46 PMP22 MTMR2
3 peripheral nervous system development GO:0007422 9.43 PMP22 NGF EGR2
4 myelination GO:0042552 9.1 PMP22 MTMR2 MPZ EGR2

Molecular functions related to Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADH dehydrogenase activity GO:0003954 8.92 MT-ND4 AIFM1

Sources for Neuropathy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....